market analyst, marketanalyst.net, market analyst llc, market research & analyst



Payment Options

You are here: Home > Publishers > MP Advisors

MP Advisors

MP Advisors is a consultancy with an exclusive focus on Pharmaceuticals/Biotechnology sectors in the US, Europe, India, Japan and Russia. The company offers insightful information on more than 200 pharma and Biotech companies around the globe as well as publishes reports on Key Opinion Leaders (Physician’s view) assessment, therapy class review of several classes (e.g. Oral anticoagulants, Hepatitis C, Obesity, Novel Drug Delivery systems, Biosimilars etc.), India and Japan generic opportunities and Paragraph IV Opportunities.

Sort By:
Page of 5
Japan Pharma  Outlook 2015: 2015 -Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives Sri Lanka Pharma Market  Outlook 2015: More beyond Importers & Distributors Global Pharma US & EU Outlook 2015  : First -In- Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies
Mature Biotech  Outlook 2015: New Therapy Ventures Pave the Way for Success India Rising Stars  Outlook 2015: Traditionally Innovation and drug discovery had taken a back seat in the Indian pharma industry with a few blips here and there Global Rising Stars  Outlook 2015: Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets.
India Pharma Outlook 2015: Accelerating growth to the next level: Moving up the value chain beyond Generics India Pharma Outlook 2015: Accelerating growth to the next level: Moving up the value chain beyond Generics Dietary Supplements: World of Opportunities In the Indian Healthcare Market
Moderate to Severe Pain: Novel Abuse Deterrent Formulation Technologies and Emergence of Novel Mechanisms in the Management of Pain New Phase of Mab biosimilar New Phase of Mab biosimilar knocks the door Biosimilar Oppurtunities In Japanknocks the door Biosimilar Oppurtunities In Japan Hematological Malignancies: Multiple Myeloma (MM) – Early and Robust Diagnosis along with New Treatment Options can have Considerable Impact on Management of the Diseas
Therapeutic Class Overview: New Avatars of Microbes Super Bugs a Growing Threat Worldwide Research and Markets: Innovative Drug Delivery Systems Opportunities for Generic & Specialty Pharmaceutical Companies Research and Markets: Therapeutic Class Overview: Psoriasis - Plaque Psoriasis & Psoriatic Arthritis - Novel Oral Drugs And Biologics To Change Future Treatment Paradigm
Therapeutic Class Overview: Treating Refractory Hematological Malignancies Research and Markets: Therapeutic Class Overview: Emergence of Biogenerics Era In Japan - It's Time to Welcome Antibody Biosimilars of Foreign Origins Soon Global Pharmaceutical and Biotechnology Outlook 2014 - India PharmaGlobal Pharmaceutical and Biotechnology Outlook 2014 - India Pharma
Global Pharmaceutical and Biotechnology Outlook 2014 - Japan Pharma Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech Global Pharmaceutical and Biotechnology Outlook 2014: Rising Stars
Global Pharmaceutical & Biotechnology Outlook 2014: Major US and EU. Global Pharmaceutical & Biotechnology Outlook 2013: Japan Pharma Global Pharmaceutical & Biotechnology Outlook 2013: Rising Stars
Global Pharmaceutical & Biotechnology Outlook 2013: Mature Biotech Global Pharmaceutical & Biotechnology Outlook 2013: Global Pharma CIPLA Market Perform, Ciplas bid for Cipla Medpro  Valuation Reasonable, No Strategic Benefit
Brisotl-Myers Squibb - Eliquis Approved for SPAF in Europe  Waiting for decision with FDA NATCO PHARMA Outperform, Great Result - More to Come  Hepatitis C: UPDATE Post AASLD 12 - Progress in IFN-Free Drugs & Vaccines - Gilead and Abbott vying for the Top Two Slots - Third Place Goes to ....?
AUROBINDO  Underperform, Great Result, But Still Not Out of Woods  SUN PHARMA  Outperform, Balance Sheet Leveraging At Play Therapy Class Overview : Hepatitis C Virus Infection
ASTRAZENECA - First in class Forxiga (dapagliflozin) approved in Europe  Diabetes portfolio may heal AstraZenecas pains Celgene - ABRAXANE + Pipeline Drugs = Long Term Growth RANBAXY - Market Perform, Inline Q3 CY12 results  Base business margin improvement still awaited